Investors & Media

What’s new.

Press releases

Press releases.

January 31st 2025

Immutep Quarterly Activities Report Q2 FY25

January 22nd 2025

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

January 6th 2025

Patient Enrolment Completed for INSIGHT-003

more

Investor updates

Investor updates.

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

more

Analyst reports

Analyst reports.

January 24th 2025

Canaccord Genuity - TACTI-003 Cohort B musings, anticipated upcoming news flow; Maintain BUY, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

December 17th 2024

Jefferies - MRK drops anti-TIGIT in 1L mNSCLC, efti more important; Buy, A$2.00 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

December 16th 2024

Wilsons - Preparedness for approval in 1L mHNSCC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

more